These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 371804)
1. Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer. Hahn RG; Bauer M; Wolter J; Creech R; Bennett JM; Wampler G Cancer Treat Rep; 1979 Mar; 63(3):513-5. PubMed ID: 371804 [TBL] [Abstract][Full Text] [Related]
2. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Perry MC; Moertel CG; Schutt AJ; Reitemeier RJ; Hahn RG Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study. Ratanatharathorn V; Baker LH; Balducci L; Talley RW; Hoogstraten B Cancer Treat Rep; 1982 May; 66(5):1231-2. PubMed ID: 7083224 [No Abstract] [Full Text] [Related]
4. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. Hahn RG; Temkin NR; Savlov ED; Perlia C; Wampler GL; Horton J; Marsh J; Carbone PP Cancer Treat Rep; 1978 Jul; 62(7):1093-5. PubMed ID: 356971 [TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study. Haas CD; Baker L; Thigpen T Cancer Treat Rep; 1981; 65(1-2):115-7. PubMed ID: 6261943 [TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of dianhydrogalactitol in advanced head and neck carcinomas. Edmonson JH; Frytak S; Letendre L; Kvols LK; Eagan RT Cancer Treat Rep; 1979; 63(11-12):2081-3. PubMed ID: 526941 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of VP-16-213 versus dianhydrogalactitol in patients with metastatic malignant melanoma. Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; O'Connell MJ; Frytak S Cancer Treat Rep; 1976 Nov; 60(11):1681-2. PubMed ID: 1021239 [No Abstract] [Full Text] [Related]
8. Phase II evaluation of dianhydrogalactitol in the treatment of advanced endometrial adenocarcinoma: a Gynecologic Oncology Group Study. Stehman FB; Blessing JA; Delgado G; Louka M Cancer Treat Rep; 1983; 67(7-8):737-8. PubMed ID: 6871892 [No Abstract] [Full Text] [Related]
9. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group. Cancer Treat Rep; 1985 Jun; 69(6):713-6. PubMed ID: 3926311 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of dianhydrogalactitol in malignant glioma. Espana P; Wiernik PH; Walker MD Cancer Treat Rep; 1978 Aug; 62(8):1199-200. PubMed ID: 210944 [No Abstract] [Full Text] [Related]
11. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study. Thigpen JT; Al-Sarraf M; Hewlett JS Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506 [TBL] [Abstract][Full Text] [Related]
12. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy. Athanassiades P; Bacoyiannes H; Kontoyiannes D Chemioterapia; 1986 Apr; 5(2):125-7. PubMed ID: 3518965 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study. Thigpen JT; Samson MK Cancer Treat Rep; 1979 Apr; 63(4):553-5. PubMed ID: 445509 [No Abstract] [Full Text] [Related]
14. Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer. Creagan ET; Eagan RT; Kvols LK Oncology; 1981; 38(5):260-1. PubMed ID: 7196561 [TBL] [Abstract][Full Text] [Related]
15. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma]. Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of dianhydrogalactitol in the treatment of children with refractory childhood malignancies: a report from the Children's Cancer Study Group. Finklestein JZ; Shore N; Krivit W; Hammond D; Higgins G Cancer Treat Rep; 1985 Nov; 69(11):1331-3. PubMed ID: 4092198 [No Abstract] [Full Text] [Related]
17. Dianhydrogalactitol and neural tumors: an in vitro, in vivo preclinical evaluation. Helson L; Rozsa P; Hajdu E; Helson JL Cancer Treat Rep; 1980; 64(12):1287-94. PubMed ID: 7471118 [TBL] [Abstract][Full Text] [Related]
18. Dianhydrogalactitol and cisplatin in combination for advanced cancer of the uterine cervix. Vogl SE; Seltzer V; Camacho F; Calanog A Cancer Treat Rep; 1982 Oct; 66(10):1809-12. PubMed ID: 6889913 [TBL] [Abstract][Full Text] [Related]
19. Phase II clinical trial of dianhydrogalactitol for remission induction in children with acute leukemia: a Southwest Oncology Group Study. Vats TS; Lui V; Trueworthy R; van Eys J Cancer Treat Rep; 1981; 65(1-2):121-2. PubMed ID: 6939482 [No Abstract] [Full Text] [Related]
20. Phase II study of vinblastine-CCNU, triazinate, and dactinomycin in advanced renal cell cancer. Hahn RG; Begg CB; Davis T Cancer Treat Rep; 1981; 65(7-8):711-13. PubMed ID: 7018680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]